Les ADS sont cotées sur le Nasdaq Global Market sous le symbole « VALN », et les actions ordinaires de la Société sont cotées sur le marché réglementé d’Euronext à Paris sous le symbole « VLA ».
OSE Immunotherapeutics a enregistré un résultat opérationnel consolidé de 43,7 millions d’euros. Les charges courantes d’exploitation s’élevaient à 39,7 millions d’euros (contre 25,2 millions d’euros ...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its ...
Le résultat opérationnel de Guerbet s’établit à 49,6 M€ en 2024, en progression de 28,2% par rapport à l’exercice précédent.
Advancement of AbbVie Inc. and OSE Immunotherapeutics strategic partnership to develop ABBV-230: in April 2024, the Hart-Scott-Rodino waiting period expired enabling teams to commence work around the ...
Launching a comprehensive review of strategic opportunities – In the fourth quarter of 2024, Atea engaged an independent global investment bank to assist the Company in identifying potential ...
WASHINGTON, March 26, 2025 (GLOBE NEWSWIRE) -- Dr. Lyudmila Sarder, MD, a highly esteemed internal medicine resident ...
After securing a $10M market cap on Solana, OmegaX Health is now expanding to Binance Smart Chain (BSC), a move that will ...
BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce ...
Portage, Michigan, March 26, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel “Manny” Maceda for election to the company’s board at the 2025 ...
A live audio webcast and replay of the presentation may be accessed for 90 days on the “News & Events” section of the company’s website at: https://www.inspiremd.com/en/events/ ...
The new entry to FDA’s database of Recognized Consensus Standards is AAMI TIR106:2024: Microbiological methods—Understanding and use of product bioburden data. Three of AAMI’s most notable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results